Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.

Dietel M, Savelov N, Salanova R, Micke P, Bigras G, Hida T, Antunez J, Guldhammer Skov B, Hutarew G, Sua LF, Akita H, Chan OSH, Piperdi B, Burke T, Khambata-Ford S, Deitz AC.

Lung Cancer. 2019 Aug;134:174-179. doi: 10.1016/j.lungcan.2019.06.012. Epub 2019 Jun 12.

PMID:
31319978
2.

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.

Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.

J Thorac Oncol. 2019 May;14(5):793-801. doi: 10.1016/j.jtho.2019.01.016. Epub 2019 Jan 31. Erratum in: J Thorac Oncol. 2019 Jul;14(7):1306.

PMID:
30711649
3.

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.

Brahmer JR, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Zhang J, Lubiniecki GM, Deitz AC, Rangwala R, Reck M.

Lancet Oncol. 2017 Dec;18(12):1600-1609. doi: 10.1016/S1470-2045(17)30690-3. Epub 2017 Nov 9.

PMID:
29129441
4.

Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.

Desai VCA, Quinlan SC, Deitz AC, He J, Holick CN, Lanes S.

J Neurooncol. 2017 Aug;134(1):89-95. doi: 10.1007/s11060-017-2489-6. Epub 2017 Jul 17.

PMID:
28717885
5.

The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys.

Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Benjet C, Bruffaerts R, de Girolamo G, de Graaf R, Maria Haro J, Kovess-Masfety V, O'Neill S, Posada-Villa J, Sasu C, Scott K, Viana MC, Xavier M.

Biol Psychiatry. 2013 May 1;73(9):904-14. doi: 10.1016/j.biopsych.2012.11.020. Epub 2013 Jan 3.

6.

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC.

Breast Cancer Res. 2008;10(4):R67. doi: 10.1186/bcr2128. Epub 2008 Aug 5.

7.

Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer.

Deitz AC, Rothman N, Rebbeck TR, Hayes RB, Chow WH, Zheng W, Hein DW, García-Closas M.

Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1543-6.

8.

Increased transcriptional activity of the CYP3A4*1B promoter variant.

Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR.

Environ Mol Mutagen. 2003;42(4):299-305.

PMID:
14673875
9.

N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women.

Deitz AC, Zheng W, Leff MA, Gross M, Wen WQ, Doll MA, Xiao GH, Folsom AR, Hein DW.

Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):905-10.

10.

N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk.

Zheng W, Deitz AC, Campbell DR, Wen WQ, Cerhan JR, Sellers TA, Folsom AR, Hein DW.

Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):233-9.

11.
12.

Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases.

Hein DW, Doll MA, Fretland AJ, Gray K, Deitz AC, Feng Y, Jiang W, Rustan TD, Satran SL, Wilkie TR Sr.

Mutat Res. 1997 May 12;376(1-2):101-6.

PMID:
9202744
13.

Identification of a novel allele at the human NAT1 acetyltransferase locus.

Doll MA, Jiang W, Deitz AC, Rustan TD, Hein DW.

Biochem Biophys Res Commun. 1997 Apr 28;233(3):584-91.

PMID:
9168895
14.

Recombinant expression and catalytic analysis of rapid and slow acetylator Syrian hamster chimeric NAT2 alleles.

Hein DW, Ferguson RJ, Doll MA, Deitz AC.

Arch Toxicol. 1997;71(5):306-13.

PMID:
9137809
15.
16.

Human N-acetylation of benzidine: role of NAT1 and NAT2.

Zenser TV, Lakshmi VM, Rustan TD, Doll MA, Deitz AC, Davis BB, Hein DW.

Cancer Res. 1996 Sep 1;56(17):3941-7.

17.

Supplemental Content

Loading ...
Support Center